116 related articles for article (PubMed ID: 23100300)
1. BCR-ABL/p62/SQSTM1: a cannibal embrace.
Auberger P
Blood; 2012 Oct; 120(17):3389-90. PubMed ID: 23100300
[TBL] [Abstract][Full Text] [Related]
2. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Goussetis DJ; Gounaris E; Wu EJ; Vakana E; Sharma B; Bogyo M; Altman JK; Platanias LC
Blood; 2012 Oct; 120(17):3555-62. PubMed ID: 22898604
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide.
Goussetis DJ; Gounaris E; Platanias LC
Autophagy; 2013 Jan; 9(1):93-4. PubMed ID: 23051894
[TBL] [Abstract][Full Text] [Related]
4. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Yoon P; Giafis N; Smith J; Mears H; Katsoulidis E; Sassano A; Altman J; Redig AJ; Tallman MS; Platanias LC
Mol Cancer Ther; 2006 Nov; 5(11):2815-23. PubMed ID: 17121928
[TBL] [Abstract][Full Text] [Related]
5. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P
Haematologica; 2007 Jun; 92(6):838-41. PubMed ID: 17550858
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Puccetti E; Güller S; Orleth A; Brüggenolte N; Hoelzer D; Ottmann OG; Ruthardt M
Cancer Res; 2000 Jul; 60(13):3409-13. PubMed ID: 10910048
[TBL] [Abstract][Full Text] [Related]
9. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells.
Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X
Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
Wu EJ; Goussetis DJ; Beauchamp E; Kosciuczuk EM; Altman JK; Eklund EA; Platanias LC
Cancer Biol Ther; 2014 Apr; 15(4):473-8. PubMed ID: 24496081
[TBL] [Abstract][Full Text] [Related]
12. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Shinohara H; Taniguchi K; Kumazaki M; Yamada N; Ito Y; Otsuki Y; Uno B; Hayakawa F; Minami Y; Naoe T; Akao Y
Cancer Lett; 2015 Apr; 360(1):28-38. PubMed ID: 25644089
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
16. Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia.
Jing HM; Yukihiro S; Ke XY; Yoshiro K; Akiharu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Oct; 10(5):413-8. PubMed ID: 12513739
[TBL] [Abstract][Full Text] [Related]
17. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
[TBL] [Abstract][Full Text] [Related]
19. Autophagy enhanced antitumor effect in K562 and K562/ADM cells using realgar transforming solution.
Wang X; Chen B; Zhao L; Zhi D; Hai Y; Song P; Li Y; Xie Q; Inam U; Wu Z; Yu L; Li H
Biomed Pharmacother; 2018 Feb; 98():252-264. PubMed ID: 29272786
[TBL] [Abstract][Full Text] [Related]
20. [Protein tyrosine kinase (PTK) activities during the induction of apoptosis by arsenic trioxide (As2O3)].
Xiao D; Sun G; Wu W
Zhonghua Xue Ye Xue Za Zhi; 1998 May; 19(5):234-6. PubMed ID: 11243118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
